Back to top

immuno-therapy: Archive

Zacks Equity Research

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.

AZNPositive Net Change BMYNegative Net Change MRKNegative Net Change LGNDNegative Net Change

Zacks Equity Research

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.

VRTXPositive Net Change UTHRNegative Net Change LGNDNegative Net Change CRSPNegative Net Change

Zacks Equity Research

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

REGNNegative Net Change PFEPositive Net Change NVONegative Net Change AMGNNegative Net Change MRNAPositive Net Change

Zacks Equity Research

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why

Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.

LGNDNegative Net Change ANIPNegative Net Change ADMANegative Net Change ENLVNegative Net Change